Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III selexipag in chronic thromboembolic pulmonary hypertension
jRCT2080223224Phase 3Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Selexipag with Placebo (2 arms). Primary endpoint: Pulmonary vascular resistance (PVR). Started Jun 2016; status: completed.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCT2080223224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223224.